Much has been said about managing herpesvirus infections since the discovery of acyclovir more than 15 years ago. This book aims to bring practical advice to the key clinician who is faced with managing these infections. It addresses questions like: there are antiviral treatments for many of these infections, but who should be getting these drugs and who should not? What are the advantages, if any, of the new drugs over the old ones? Which patients should be targeted for intervention? What is the clinical reality of antiviral resistance? Where do the up and coming vaccines fit into the picture? When should therapy be discontinued or reassessed? How are patients presenting other than chorioretinitis in AIDS or pneumonitis in transplantation? The contributing clinician scientists deal with these questions and many more.
Listed by Biological Abstracts/RRM, BIOSIS, volume 48, issue 8, August 1995 Covered by Current Contents, Life Sciences (ISI), volume 39, no. 2, Januari 1996, p. 12
